With necessary lipid measurements captured on nearly all of the women, the analysis is large, involving 27,533 women aged 45 years or older. This is a primary prevention population -these women were all free of self-reported cardiovascular disease and cancer at baseline. After baseline risk factor measurements, the women underwent follow-up over a median of 17.2 years for incident coronary events, including nonfatal myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, and coronary death. An Endpoints Committee adjudicated events, which occurred in 1,070 women.
Another strength of the study is that the laboratory performing the measurements participates in the Centers for Disease Control and Prevention's Lipid Standardization Program.
Ultimately, when we measure lipid parameters, and compare across studies and patients, we want to know that we are measuring the same thing in the same way. This important laboratory program provides accuracy-based standards for total cholesterol, triglycerides, HDL cholesterol (HDL-C), and apoB. It is important to note that non-HDL-C and Friedewald-estimated LDL-C 5 use inputs from these standardized measures. The other measures in this study (direct LDL-C and LDL-P) are not part of the standardization program.
The study uses a direct assay for LDL-C, specifically the Roche direct homogeneous assay. On the surface, it would seem a virtue to use a direct assay, as it avoids the challenges of LDL-C estimation. 6, 7 However, not all direct techniques are created equal. Whereas the traditional technique is ultracentrifugation-based, the Roche assay is detergent-based. Moreover, . 6 A prior analysis showed that the Roche direct LDL assay measures LDL and IDL, but not Lp(a), and showed a significant negative bias due to suboptimal calibration between the Roche assay and beta-quantification. 8 Among four homogeneous direct LDL-C assays, the Roche assay had the highest total error at 41.6%. 9 These issues do not negate the importance of this study (especially given the authors also conducted analyses with Friedewald-estimated LDL-C), but must be taken into consideration when comparing the results with other literature.
Going into the analysis, it is also important to understand that LDL-C, non-HDL-C, apoB, and LDL-P, by nature, are expected to carry unique information. LDL-C is the cholesterol assay. On the surface, it would seem a virtue to use a direct assay, as it avoids the he e c cha ha h ll ll llen n enge ge ges s s o of LDL-C estimation. 6, 7 However, not all direct techniques are created equal. Whereas the r rad ad dit it itio io iona nal l l te te tec c chni ni iqu qu que e is ultracentrifugation-based d d, , th h he Roche assa ay y y is d det et ete er ergent-based. Moreover, h h he L LDL-C of f c com om ommo mon n pa pa parl rl rlan an anc ce ce ---a a as s e e est tabli ish h hed b b by y y th he e e tr trad ad dit it tio ion n nal l de defi fi fini iti ion on n u use ]. ]. 6 6 6 A A A p p pri ri rior or o a a ana na naly ly lysi si sis s s showed content of LDL, IDL, and Lp(a), while non-HDL-C adds the cholesterol content of VLDL. ApoB can be viewed as the particle-based counterpart of non-HDL-C as there is one apoB particle per atherogenic lipoprotein particle. In contrast, LDL-P in theory is the particle concentration counterpart of LDL-C, assuming that we are quantifying the cholesterol content and particle concentrations from the same lipoprotein fractions.
Considering these parameters, Mora and colleagues address two key questions: 1) How often is there discordance of LDL-C with non-HDL-C, apoB, or LDL-P? 2) Does discordance matter in terms of coronary prognosis? Amidst a field of research wherein studies have often focused on pitting one type of lipid measurement against another to examine average risk in broad populations, the authors should be commended for this more clinically-relevant form of analysis. As the authors insightfully point out, "the clinical utility of these measures may only become apparent among individuals for whom levels are inconsistent (discordant) with LDL-C." 1 We submit that because discordance is defined at the level of the patient, discordance analysis should become the preferred standard for future observational studies comparing lipid parameters.
To perform a discordance analysis, Mora and colleagues use the median levels of LDL-C (121 mg/dL), non-HDL-C (154 mg/dL), apoB (100 mg/dL), and LDL-P (1216 nmol/L). The authors then categorize women as discordant if the LDL-C is median and the comparison measure (non-HDL-C, apoB, LDL-P) is <median, or vice versa. The remaining women are classified as concordant. Discordance is present in 11.6% of women in comparison with non-HDL-C, 18.9% with apoB, and 24.3% with LDL-P. It is interesting that the greatest discordance exists between LDL-C and LDL-P, rather than between LDL-C and one of the other measures including additional lipoprotein fractions.
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Moreover, some of the significant findings were lost when using Friedewald-estimated LDL-C instead of direct LDL-C. This highlights the need for additional investigations using ultracentrifugation-based direct LDL-C and novel methods for LDL-C estimation. 7 Another limitation of this current study is that it is not reported how many patients were on statins at baseline or initiated a statin during follow-up. This can impact coronary risk prediction, and confound the relationship between baseline lipid parameters and outcomes. Not racked more closely with LDL-P. 11 More recently, Dr. Otvos, along with other c c coll ll lea eagu gu gues es es, , , ncluding Dr. Mora, reached a similar result in the more diverse Multi-Ethnic Study of At Athe he hero ro osc scle le lero ro r s s sis co co coh hort. While percutaneous coronary intervention and coronary artery bypass grafting are clinically important outcomes, they are subject to a higher risk of bias and geographic variation.
Therefore, it would have been nice to see if results were still robust using hard endpoints of MI and coronary death. This is especially the case given revascularization outcomes were not included in the 2013 ACC/AHA guidelines risk calculator. 4 Another consideration as this line of research matures is definitions of discordance. To define discordance, the authors chose median cutpoints because there is no physiologic cutpoint for discordance. However, greater discordance between LDL-C and non-HDL-C occurs at lower LDL-C levels. 15 It is notable that the methods to date for defining discordance have been discordant, ranging from 12 percentile units difference 12 to Framingham percentiles and guideline cutpoints. 16 In moving forward, we as a research community should settle upon a standard approach to discordance analysis, so that we can best synthesize the studies, and reach the ultimate goal of translating the concept into optimizing care of the individual patient.
In summary, the authors nicely have demonstrated that discordance is common, that this discordance may lead to over-or under-estimation of clinically significant coronary risk, and this may have important implications for developing future risk prediction calculators. However, further study is needed regarding how to best apply these findings in the clinical management of individual discordant patients, especially in the new era of "abandoning" specific lipid targets.
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